Comparative Effectiveness Funded By Public-Private Trust Proposed In House
Executive Summary
Efforts to enhance the role and resources for research comparing the effectiveness of drugs and medical devices gained another boost May 7, with legislation introduced by Reps. Tom Allen, D-Maine, and Jo Ann Emerson, R-Mo
You may also be interested in...
Large Payers, Including CMS, PBMs, Mostly Absent From PCORI Board
With some very overt participation in comparative effectiveness research, one may have expected representatives from traditional large health care organizations or pharmacy benefit managers to be appointed to the Patient-Centered Outcomes Research Institute first board of governors. However, they were left off the board, announced Sept. 23.
Large Payers, Including CMS, PBMs, Mostly Absent From PCORI Board
With some very overt participation in comparative effectiveness research, one may have expected representatives from traditional large health care organizations or pharmacy benefit managers to be appointed to the Patient-Centered Outcomes Research Institute first board of governors. However, they were left off the board, announced Sept. 23.
Health Plans Readying For Comparative Effectiveness Push Next Year
With drug spending on the rise, health plans expect new federal policy on comparative effectiveness is imminent.